ROSEVILLE, Calif., Jan. 15 /PRNewswire/ -- CoolTouch Inc., a pioneering manufacturer of medical lasers, states the CoolTouch CoolLipo(TM) 1320 wavelength laser was designed to be superior to the Cynosure SmartLipo 1064 technology and does not infringe. Among other reasons, the CoolLipo incorporates state-of-the-art 1320 nm laser technology, coated fibers, and a variety of handpieces which allow the fiber to be extended beyond the end of the cannula, thereby not infringing the '873 patent whose claims require that the fiber must be adjacent to the end of the cannula. The CoolTouch advantage of extending the fiber beyond the cannula helps prevent inadvertent heating of the cannula and assists in cutting connective tissue.

Additionally, thousands of pulsed Nd:Yag lasers with specifications identical to the SmartLipo have been sold since the mid-1980s.

A popular acne drug may raise cholesterol levels.

People who take the acne drug Accutane (isoretinoin), may be at risk for high cholesterol. Researchers from the University of California, San Franscisco, looked at the blood tests of almost 13,772 patients who took the drug between 1995 and 2002. Looking closely at those who had normal blood tests before taking the drug, the researchers noted that 44 percent developed high triglycerides, 31 percent developed high cholesterol and 11 percent developed high liver enzymes while taking Accutane. While Roche, the maker of Accutane, does warn patients that the drug may cause increased triglycerides, cholesterol and liver enzymes, this is the first study to show how significantly blood levels of these elements change. The study found that blood tests tend to go back to normal once patients stop taking the drug.

TeleTech Holdings Q3 Revenues Up 11% - Quick Facts [TTEC]

11/8/2007 10:33:10 PM Thursday, TeleTech Holdings Inc. (TTEC) reported preliminary financial results for the third quarter 2007, due to self-initiated review of accounting and likely restatement of prior period financial statements.

TeleTech reported third quarter revenues of $335.8 million, up 10.5% from $303.80 million in the prior-year quarter. Revenues from services performed for clients in offshore locations grew about 33% to $136.5 million year-over-year.

Preliminary total operating expenses for the latest third quarter were $309.86 million, while income from operations were at $25.94 million.

The company noted that sale of business resulted in a pre-tax disposition charge of $7.0 million, including $2 million of cash related expenses, net of a software sale, during the third quarter.

Healthy Woman Today Newsletter June 2007

There's something like a line of gold thread running through a man's words when he talks to his daughter, and gradually over the years it gets to be long enough for you to pick up in your hands and weave into a cloth that feels like love itself.
— John Gregory Brown, author.

CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit

ROSEVILLE, Calif., Jan. 15 /PRNewswire/ -- CoolTouch Inc., a pioneering manufacturer of medical lasers, states the CoolTouch CoolLipo(TM) 1320 wavelength laser was designed to be superior to the Cynosure SmartLipo 1064 technology and does not infringe. Among other reasons, the CoolLipo incorporates state-of-the-art 1320 nm laser technology, coated fibers, and a variety of handpieces which allow the fiber to be extended beyond the end of the cannula, thereby not infringing the '873 patent whose claims require that the fiber must be adjacent to the end of the cannula. The CoolTouch advantage of extending the fiber beyond the cannula helps prevent inadvertent heating of the cannula and assists in cutting connective tissue.

Additionally, thousands of pulsed Nd:Yag lasers with specifications identical to the SmartLipo have been sold since the mid-1980s.

A popular acne drug may raise cholesterol levels.

People who take the acne drug Accutane (isoretinoin), may be at risk for high cholesterol. Researchers from the University of California, San Franscisco, looked at the blood tests of almost 13,772 patients who took the drug between 1995 and 2002. Looking closely at those who had normal blood tests before taking the drug, the researchers noted that 44 percent developed high triglycerides, 31 percent developed high cholesterol and 11 percent developed high liver enzymes while taking Accutane. While Roche, the maker of Accutane, does warn patients that the drug may cause increased triglycerides, cholesterol and liver enzymes, this is the first study to show how significantly blood levels of these elements change. The study found that blood tests tend to go back to normal once patients stop taking the drug.

TeleTech Holdings Q3 Revenues Up 11% - Quick Facts [TTEC]

11/8/2007 10:33:10 PM Thursday, TeleTech Holdings Inc. (TTEC) reported preliminary financial results for the third quarter 2007, due to self-initiated review of accounting and likely restatement of prior period financial statements.

TeleTech reported third quarter revenues of $335.8 million, up 10.5% from $303.80 million in the prior-year quarter. Revenues from services performed for clients in offshore locations grew about 33% to $136.5 million year-over-year.

Preliminary total operating expenses for the latest third quarter were $309.86 million, while income from operations were at $25.94 million.

The company noted that sale of business resulted in a pre-tax disposition charge of $7.0 million, including $2 million of cash related expenses, net of a software sale, during the third quarter.

Healthy Woman Today Newsletter June 2007

There's something like a line of gold thread running through a man's words when he talks to his daughter, and gradually over the years it gets to be long enough for you to pick up in your hands and weave into a cloth that feels like love itself.
— John Gregory Brown, author.